Free Trial
OTCMKTS:ISCO

International Stem Cell (ISCO) Stock Price, News & Analysis

International Stem Cell logo
$0.12 0.00 (0.00%)
As of 04/3/2025

About International Stem Cell Stock (OTCMKTS:ISCO)

Key Stats

Today's Range
$0.12
$0.12
50-Day Range
$0.09
$0.13
52-Week Range
$0.05
$0.20
Volume
N/A
Average Volume
4,989 shs
Market Capitalization
$980,490.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

Remove Ads

International Stem Cell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

ISCO MarketRank™: 

International Stem Cell scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for International Stem Cell.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of International Stem Cell is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of International Stem Cell is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about International Stem Cell's valuation and earnings.
  • Percentage of Shares Shorted

    0.01% of the float of International Stem Cell has been sold short.
  • Short Interest Ratio / Days to Cover

    International Stem Cell has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    International Stem Cell does not currently pay a dividend.

  • Dividend Growth

    International Stem Cell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the float of International Stem Cell has been sold short.
  • Short Interest Ratio / Days to Cover

    International Stem Cell has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Search Interest

    1 people have searched for ISCO on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, International Stem Cell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    81.48% of the stock of International Stem Cell is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about International Stem Cell's insider trading history.
Receive ISCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for International Stem Cell and its competitors with MarketBeat's FREE daily newsletter.

ISCO Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Headlines

ISCO Stock Analysis - Frequently Asked Questions

International Stem Cell's stock was trading at $0.0813 at the beginning of the year. Since then, ISCO shares have increased by 50.7% and is now trading at $0.1225.
View the best growth stocks for 2025 here
.

International Stem Cell Co. (OTCMKTS:ISCO) issued its quarterly earnings data on Friday, May, 17th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $2.22 million for the quarter.

Shares of ISCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that International Stem Cell investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Amarantus BioScience (AMBS), Fulcrum Therapeutics (FULC), Kutcho Copper (KCCFF), B2Gold (BTG) and Auxly Cannabis Group (CBWTF).

Company Calendar

Last Earnings
5/17/2019
Today
4/04/2025
Next Earnings (Estimated)
6/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ISCO
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-130,000.00
Pretax Margin
-7.95%

Debt

Sales & Book Value

Annual Sales
$7.79 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
1,482,000
Market Cap
$980,490.00
Optionable
Not Optionable
Beta
0.05

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (OTCMKTS:ISCO) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners